A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Amgen, Inc.
Start Date
February 20, 2019
End Date
February 20, 2024
Administered By
Duke Cancer Institute
Awarded By
Amgen, Inc.
Start Date
February 20, 2019
End Date
February 20, 2024